Spring Bank Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SBPH)

$3.51
+0.02 (+0.57 %)
(As of 09/23/2019 11:12 AM ET)
Today's Range
$3.47
Now: $3.51
$3.51
50-Day Range
$3.3937
MA: $3.94
$4.78
52-Week Range
$3.32
Now: $3.51
$15.00
Volume2,226 shs
Average Volume19,197 shs
Market Capitalization$57.77 million
P/E RatioN/A
Dividend YieldN/A
Beta0.51
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV). The company is also developing STimulator of INterferon Genes agonist product candidate, including SB 11285, an immunotherapeutic agent for the potential treatment of selected cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBPH
CUSIPN/A
Phone508-473-5993

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$350,000.00
Book Value$3.40 per share

Profitability

Net Income$-22,850,000.00

Miscellaneous

Employees29
Market Cap$57.77 million
Next Earnings Date10/24/2019 (Estimated)
OptionableNot Optionable

Receive SBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SBPH and its competitors with MarketBeat's FREE daily newsletter.


Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions

What is Spring Bank Pharmaceuticals' stock symbol?

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

How were Spring Bank Pharmaceuticals' earnings last quarter?

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) released its quarterly earnings results on Wednesday, July, 31st. The company reported ($0.28) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.56) by $0.28. View Spring Bank Pharmaceuticals' Earnings History.

When is Spring Bank Pharmaceuticals' next earnings date?

Spring Bank Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for Spring Bank Pharmaceuticals.

What price target have analysts set for SBPH?

6 equities research analysts have issued 1-year target prices for Spring Bank Pharmaceuticals' stock. Their predictions range from $10.00 to $29.00. On average, they anticipate Spring Bank Pharmaceuticals' share price to reach $21.60 in the next twelve months. This suggests a possible upside of 515.4% from the stock's current price. View Analyst Price Targets for Spring Bank Pharmaceuticals.

What is the consensus analysts' recommendation for Spring Bank Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spring Bank Pharmaceuticals.

Has Spring Bank Pharmaceuticals been receiving favorable news coverage?

News headlines about SBPH stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Spring Bank Pharmaceuticals.

Who are some of Spring Bank Pharmaceuticals' key competitors?

What other stocks do shareholders of Spring Bank Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), Associated British Foods (ABF), Chaarat Gold (CGH), First Data (FDC), Apollo Global Management (APO), tronc (TRNC) and China Unicom (Hong Kong) (CHU).

Who are Spring Bank Pharmaceuticals' key executives?

Spring Bank Pharmaceuticals' management team includes the folowing people:
  • Mr. Martin J. Driscoll, Pres, CEO & Director (Age 60)
  • Dr. Radhakrishna P. Iyer, Co-Founder, Chief Scientific Officer & Director (Age 69)
  • Dr. Nezam H. Afdhal, Chief Medical Officer (Age 62)
  • Mr. Jonathan P. Freve CPA, CFO & Treasurer (Age 41)
  • Mr. Donald Mitchell MBA, VP of Operations & Corp. Devel.

When did Spring Bank Pharmaceuticals IPO?

(SBPH) raised $14 million in an IPO on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities served as the underwriter for the IPO.

Who are Spring Bank Pharmaceuticals' major shareholders?

Spring Bank Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.06%), AXA (2.30%), BlackRock Inc. (1.24%), Northern Trust Corp (1.14%), Renaissance Technologies LLC (0.80%) and Paloma Partners Management Co (0.38%). Company insiders that own Spring Bank Pharmaceuticals stock include Jonathan Freve, Martin J Driscoll and Scott Andrew Smith. View Institutional Ownership Trends for Spring Bank Pharmaceuticals.

Which institutional investors are selling Spring Bank Pharmaceuticals stock?

SBPH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morse Asset Management Inc, Vanguard Group Inc., Bank of New York Mellon Corp and Wells Fargo & Company MN. View Insider Buying and Selling for Spring Bank Pharmaceuticals.

Which institutional investors are buying Spring Bank Pharmaceuticals stock?

SBPH stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Paloma Partners Management Co, Susquehanna International Group LLP, Morgan Stanley, Jane Street Group LLC, Arcadia Investment Management Corp MI, AXA and Hikari Power Ltd. Company insiders that have bought Spring Bank Pharmaceuticals stock in the last two years include Jonathan Freve, Martin J Driscoll and Scott Andrew Smith. View Insider Buying and Selling for Spring Bank Pharmaceuticals.

How do I buy shares of Spring Bank Pharmaceuticals?

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Spring Bank Pharmaceuticals' stock price today?

One share of SBPH stock can currently be purchased for approximately $3.51.

How big of a company is Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals has a market capitalization of $57.77 million and generates $350,000.00 in revenue each year. The company earns $-22,850,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe.View Additional Information About Spring Bank Pharmaceuticals.

What is Spring Bank Pharmaceuticals' official website?

The official website for Spring Bank Pharmaceuticals is http://springbankpharm.com/.

How can I contact Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]


MarketBeat Community Rating for Spring Bank Pharmaceuticals (NASDAQ SBPH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  180 (Thanks for Voting!)
Underperform Votes:  193 (Thanks for Voting!)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Featured Article: Management Fee

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel